Sinary Bio-Technology Holdings Group

Sinovent, officially known as Sinary Bio-Technology Holdings Group, is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule drugs. The company targets high-prevalence diseases with significant unmet medical needs, particularly in oncology, metabolic disorders, and autoimmune conditions. Its lead candidate, XNW3009 (Epsiurad), is a potent URAT1 inhibitor currently in Phase 3 clinical trials for the treatment of gout and hyperuricemia. Sinovent leverages advanced drug discovery platforms, including a specialized PROTAC technology, to address traditionally undruggable targets. Headquartered in Suzhou, China, the company maintains a global presence with R&D and clinical operations in Beijing, Shanghai, Boston, and Sydney.